Baseline characteristics of LyMa-101 and LyMa-ITT populations (reattribution of nonrandomized patient) before and after PSM
| Population . | Before matching (PS set) . | After PSM (matching set) . | Fisher test after PSM, P value . | ||
|---|---|---|---|---|---|
| Number . | LyMa, n = 148∗ . | LyMa-101, n = 84 . | R group, n = 82 . | O group, n = 82 . | |
| Sex | |||||
| Male | 115 (77.7%) | 61 (73%) | 62 (75.6%) | 59 (72%) | .72 |
| Female | 33 (22.3%) | 23 (27%) | 20 (24.4%) | 23 (28%) | |
| MIPI risk group | |||||
| Low | 79 (53.4%) | 46 (55%) | 42 (51.2%) | 44 (53.7%) | .93 |
| Intermediate | 842 (28.4%) | 24 (28%) | 24 (29.3%) | 24 (29.3%) | |
| High | 27 (18.2%) | 14 (17%) | 16 (19.5%) | 14 (17.1%) | |
| Ann Arbor stage | |||||
| II | 9 (6.1%) | 2 (3%) | 2 (2.4%) | 2 (2.4%) | 1 |
| III | 15 (10.1%) | 6 (7%) | 7 (8.5%) | 6 (7.3%) | |
| IV | 124 (83.8%) | 76 (90%) | 73 (89%) | 74 (90.2%) | |
| B symptoms | |||||
| No | 103 (69.6%) | 68 (81%) | 67 (81.7%) | 66 (80.5%) | 1 |
| Yes | 45 (30.4%) | 16 (19%) | 15 (18.3%) | 16 (19.5%) | |
| Blastoid variant | |||||
| No | 129 (87.2%) | 70 (83%) | 70 (85.4%) | 70 (85.4%) | 1 |
| Yes | 19 (12.8%) | 14 (17%) | 12 (14.6%) | 12 (14.6%) | |
| Population . | Before matching (PS set) . | After PSM (matching set) . | Fisher test after PSM, P value . | ||
|---|---|---|---|---|---|
| Number . | LyMa, n = 148∗ . | LyMa-101, n = 84 . | R group, n = 82 . | O group, n = 82 . | |
| Sex | |||||
| Male | 115 (77.7%) | 61 (73%) | 62 (75.6%) | 59 (72%) | .72 |
| Female | 33 (22.3%) | 23 (27%) | 20 (24.4%) | 23 (28%) | |
| MIPI risk group | |||||
| Low | 79 (53.4%) | 46 (55%) | 42 (51.2%) | 44 (53.7%) | .93 |
| Intermediate | 842 (28.4%) | 24 (28%) | 24 (29.3%) | 24 (29.3%) | |
| High | 27 (18.2%) | 14 (17%) | 16 (19.5%) | 14 (17.1%) | |
| Ann Arbor stage | |||||
| II | 9 (6.1%) | 2 (3%) | 2 (2.4%) | 2 (2.4%) | 1 |
| III | 15 (10.1%) | 6 (7%) | 7 (8.5%) | 6 (7.3%) | |
| IV | 124 (83.8%) | 76 (90%) | 73 (89%) | 74 (90.2%) | |
| B symptoms | |||||
| No | 103 (69.6%) | 68 (81%) | 67 (81.7%) | 66 (80.5%) | 1 |
| Yes | 45 (30.4%) | 16 (19%) | 15 (18.3%) | 16 (19.5%) | |
| Blastoid variant | |||||
| No | 129 (87.2%) | 70 (83%) | 70 (85.4%) | 70 (85.4%) | 1 |
| Yes | 19 (12.8%) | 14 (17%) | 12 (14.6%) | 12 (14.6%) | |
In this analysis, 148 and 84 patients in the R and O groups, respectively, were matched based on baseline characteristics, resulting in 82 patients in each group. Survival curves were drawn from inclusion. Of the 149 LyMa-ITT patients, 1 patient withdrew his consent, leading to 148 patients analyzed. Of the 86 patients included in LyMa-101, 1 withdrew his consent and 1 had missing data for matching.
Fisher test was performed between matched populations.
A total of 120 randomized and 28 nonrandomized patients.